

Catia Cilloniz

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4620254/catia-cilloniz-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

408
papers

15,932
citations

61
h-index

116
g-index

487
ext. papers

20,645
ext. citations

7.5
avg, IF

6.64
L-index

#	Paper	IF	Citations
408	Supine body position as a risk factor for nosocomial pneumonia in mechanically ventilated patients: a randomised trial. <i>Lancet, The</i> , 1999 , 354, 1851-8	40	1014
407	Incidence, risk, and prognosis factors of nosocomial pneumonia in mechanically ventilated patients. <i>The American Review of Respiratory Disease</i> , 1990 , 142, 523-8		749
406	Significance of the isolation of <i>Candida</i> species from respiratory samples in critically ill, non-neutropenic patients. An immediate postmortem histologic study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1997 , 156, 583-90	10.2	676
405	Severe community-acquired pneumonia. Epidemiology and prognostic factors. <i>The American Review of Respiratory Disease</i> , 1991 , 144, 312-8		469
404	European Respiratory Society guidelines for the management of adult bronchiectasis. <i>European Respiratory Journal</i> , 2017 , 50,	13.6	451
403	International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: Guidelines for the management of hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), and Associação Latinoamericana de Tórax (ALAT). <i>European Respiratory Journal</i> , 2017 , 50,	13.6	425
402	Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. <i>Lancet Respiratory Medicine</i> , 2014 , 2, 395-404	35.1	405
401	Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1998 , 157, 1498-505	10.2	351
400	Risk factors for community-acquired pneumonia in adults in Europe: a literature review. <i>Thorax</i> , 2013 , 68, 1057-65	7.3	341
399	Defining, treating and preventing hospital acquired pneumonia: European perspective. <i>Intensive Care Medicine</i> , 2009 , 35, 9-29	14.5	318
398	Clinical diagnosis of ventilator associated pneumonia revisited: comparative validation using immediate post-mortem lung biopsies. <i>Thorax</i> , 1999 , 54, 867-73	7.3	317
397	Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 313, 677-86	27.4	306
396	Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. <i>Clinical Infectious Diseases</i> , 2003 , 36, 389-95	11.6	295
395	Community-acquired pneumonia. <i>Lancet, The</i> , 2015 , 386, 1097-108	40	267
394	Bacterial colonization patterns in mechanically ventilated patients with traumatic and medical head injury. Incidence, risk factors, and association with ventilator-associated pneumonia. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1999 , 159, 188-98	10.2	265
393	Community-acquired pneumonia due to gram-negative bacteria and <i>Pseudomonas aeruginosa</i> : incidence, risk, and prognosis. <i>Archives of Internal Medicine</i> , 2002 , 162, 1849-58		237
392	Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial. <i>Lancet Infectious Diseases, The</i> , 2018 , 18, 285-295	25.5	207

391	Etiology of Non-Cystic Fibrosis Bronchiectasis in Adults and Its Correlation to Disease Severity. <i>Annals of the American Thoracic Society</i> , 2015 , 12, 1764-70	4.7	186
390	Microbial aetiology of community-acquired pneumonia and its relation to severity. <i>Thorax</i> , 2011 , 66, 340-63	7.3	185
389	Rethinking the concepts of community-acquired and health-care-associated pneumonia. <i>Lancet Infectious Diseases</i> , 2010 , 10, 279-87	25.5	154
388	Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease. <i>Thorax</i> , 2015 , 70, 984-9	7.3	153
387	Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research. <i>European Respiratory Journal</i> , 2017 , 49,	13.6	149
386	Pneumonia acquired in the community through drug-resistant <i>Streptococcus pneumoniae</i> . <i>American Journal of Respiratory and Critical Care Medicine</i> , 1999 , 159, 1835-42	10.2	147
385	Nosocomial pneumonia in the intensive care unit acquired by mechanically ventilated versus nonventilated patients. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010 , 182, 1533-9	10.2	125
384	Impact of age and comorbidity on cause and outcome in community-acquired pneumonia. <i>Chest</i> , 2013 , 144, 999-1007	5.3	122
383	The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity. <i>Lancet Respiratory Medicine</i> , 2021 , 9, 622-642	35.1	121
382	Impact of alcohol abuse in the etiology and severity of community-acquired pneumonia. <i>Chest</i> , 2006 , 129, 1219-25	5.3	118
381	Severe community-acquired pneumonia: validation of the Infectious Diseases Society of America/American Thoracic Society guidelines to predict an intensive care unit admission. <i>Clinical Infectious Diseases</i> , 2009 , 48, 377-85	11.6	116
380	Increased incidence of co-infection in critically ill patients with influenza. <i>Intensive Care Medicine</i> , 2017 , 43, 48-58	14.5	109
379	Causes and predictors of nonresponse to treatment of intensive care unit-acquired pneumonia. <i>Critical Care Medicine</i> , 2004 , 32, 938-45	1.4	108
378	The Role of Neutrophil Elastase Inhibitors in Lung Diseases. <i>Chest</i> , 2017 , 152, 249-262	5.3	106
377	New Sepsis Definition (Sepsis-3) and Community-acquired Pneumonia Mortality. A Validation and Clinical Decision-Making Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017 , 196, 1287-1297	10.2	103
376	Microbial Etiology of Pneumonia: Epidemiology, Diagnosis and Resistance Patterns. <i>International Journal of Molecular Sciences</i> , 2016 , 17,	6.3	100
375	Multidrug-resistant pathogens in hospitalised patients coming from the community with pneumonia: a European perspective. <i>Thorax</i> , 2013 , 68, 997-9	7.3	96
374	Programmed Disarming of the neutrophil proteome reduces the magnitude of inflammation. <i>Nature Immunology</i> , 2020 , 21, 135-144	19.1	89

373	Current gaps in sepsis immunology: new opportunities for translational research. <i>Lancet Infectious Diseases, The</i> , 2019 , 19, e422-e436	25.5	88
372	Prognostic factors of severe Legionella pneumonia requiring admission to ICU. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1997 , 156, 1467-72	10.2	87
371	Pneumonia severity index class v patients with community-acquired pneumonia: characteristics, outcomes, and value of severity scores. <i>Chest</i> , 2007 , 132, 515-22	5.3	85
370	Risk factors associated with potentially antibiotic-resistant pathogens in community-acquired pneumonia. <i>Annals of the American Thoracic Society</i> , 2015 , 12, 153-60	4.7	84
369	The EMBARC European Bronchiectasis Registry: protocol for an international observational study. <i>ERJ Open Research</i> , 2016 , 2,	3.5	84
368	Relationship between SARS-CoV-2 infection and the incidence of ventilator-associated lower respiratory tract infections: a European multicenter cohort study. <i>Intensive Care Medicine</i> , 2021 , 47, 188-198	14.5	80
367	Community-acquired polymicrobial pneumonia in the intensive care unit: aetiology and prognosis. <i>Critical Care</i> , 2011 , 15, R209	10.8	78
366	Improving outcomes in elderly patients with community-acquired pneumonia by adhering to national guidelines: Community-Acquired Pneumonia Organization International cohort study results. <i>Archives of Internal Medicine</i> , 2009 , 169, 1515-24		78
365	Corticosteroid treatment in critically ill patients with severe influenza pneumonia: a propensity score matching study. <i>Intensive Care Medicine</i> , 2018 , 44, 1470-1482	14.5	76
364	Cytokine activation patterns and biomarkers are influenced by microorganisms in community-acquired pneumonia. <i>Chest</i> , 2012 , 141, 1537-1545	5.3	75
363	Treatment guidelines and outcomes of hospital-acquired and ventilator-associated pneumonia. <i>Clinical Infectious Diseases</i> , 2010 , 51 Suppl 1, S48-53	11.6	75
362	The Role of Viruses in the Aetiology of Community-Acquired Pneumonia in Adults. <i>Antiviral Therapy</i> , 2006 , 11, 351-359	1.6	75
361	Pneumonic and nonpneumonic exacerbations of COPD: inflammatory response and clinical characteristics. <i>Chest</i> , 2013 , 144, 1134-1142	5.3	71
360	Procalcitonin (PCT) levels for ruling-out bacterial coinfection in ICU patients with influenza: A CHAID decision-tree analysis. <i>Journal of Infection</i> , 2016 , 72, 143-51	18.9	70
359	A prediction rule for estimating the risk of bacteremia in patients with community-acquired pneumonia. <i>Clinical Infectious Diseases</i> , 2009 , 49, 409-16	11.6	70
358	Advances in antibiotic therapy in the critically ill. <i>Critical Care</i> , 2016 , 20, 133	10.8	70
357	Laboratory diagnosis of pneumonia in the molecular age. <i>European Respiratory Journal</i> , 2016 , 48, 1764-1778	17.8	69
356	Diagnosing ventilator-associated pneumonia. <i>New England Journal of Medicine</i> , 2004 , 350, 433-5	59.2	68

355	Microbial aetiology of healthcare associated pneumonia in Spain: a prospective, multicentre, case-control study. <i>Thorax</i> , 2013 , 68, 1007-14	7.3	66
354	Community-Acquired Pneumonia Due to Multidrug- and Non-Multidrug-Resistant <i>Pseudomonas aeruginosa</i> . <i>Chest</i> , 2016 , 150, 415-25	5.3	66
353	Pulmonary Function and Radiologic Features in Survivors of Critical COVID-19: A 3-Month Prospective Cohort. <i>Chest</i> , 2021 , 160, 187-198	5.3	64
352	Lymphopenic community acquired pneumonia as signature of severe COVID-19 infection. <i>Journal of Infection</i> , 2020 , 80, e23-e24	18.9	62
351	Efficacy and safety of trimodulin, a novel polyclonal antibody preparation, in patients with severe community-acquired pneumonia: a randomized, placebo-controlled, double-blind, multicenter, phase II trial (CIGMA study). <i>Intensive Care Medicine</i> , 2018 , 44, 438-448	14.5	62
350	Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial. <i>Clinical Infectious Diseases</i> , 2008 , 46, 1499-509	11.6	62
349	Intensive care unit-acquired pneumonia due to <i>Pseudomonas aeruginosa</i> with and without multidrug resistance. <i>Journal of Infection</i> , 2017 , 74, 142-152	18.9	61
348	Corticosteroids in Patients Hospitalized With Community-Acquired Pneumonia: Systematic Review and Individual Patient Data Metaanalysis. <i>Clinical Infectious Diseases</i> , 2018 , 66, 346-354	11.6	59
347	Bacterial co-infection with H1N1 infection in patients admitted with community acquired pneumonia. <i>Journal of Infection</i> , 2012 , 65, 223-30	18.9	59
346	Bronchiectasis in India: results from the European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) and Respiratory Research Network of India Registry. <i>The Lancet Global Health</i> , 2019 , 7, e1269-e1279	13.6	57
345	Burden and risk factors for community-acquired pneumonia: a multinational point prevalence study of hospitalised patients. <i>European Respiratory Journal</i> , 2018 , 52,	13.6	56
344	Decrease in mortality in severe community-acquired pneumococcal pneumonia: impact of improving antibiotic strategies (2000-2013). <i>Chest</i> , 2014 , 146, 22-31	5.3	56
343	High-flow nasal oxygen in patients with COVID-19-associated acute respiratory failure. <i>Critical Care</i> , 2021 , 25, 58	10.8	54
342	Readmission for Acute Exacerbation within 30 Days of Discharge Is Associated with a Subsequent Progressive Increase in Mortality Risk in COPD Patients: A Long-Term Observational Study. <i>PLoS ONE</i> , 2016 , 11, e0150737	3.7	53
341	The burden of community-acquired bacterial pneumonia in the era of antibiotic resistance. <i>Expert Review of Respiratory Medicine</i> , 2019 , 13, 139-152	3.8	53
340	Community-acquired pneumonia in outpatients: aetiology and outcomes. <i>European Respiratory Journal</i> , 2012 , 40, 931-8	13.6	51
339	The Effect of Macrolide Resistance on the Presentation and Outcome of Patients Hospitalized for <i>Streptococcus pneumoniae</i> Pneumonia. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015 , 191, 1265-72	10.2	50
338	Challenges in severe community-acquired pneumonia: a point-of-view review. <i>Intensive Care Medicine</i> , 2019 , 45, 159-171	14.5	49

337	Pandemic and post-pandemic influenza A (H1N1) infection in critically ill patients. <i>Critical Care</i> , 2011 , 15, R286	10.8	49
336	Community-acquired pneumonia related to intracellular pathogens. <i>Intensive Care Medicine</i> , 2016 , 42, 1374-86	14.5	48
335	Burden of pneumococcal community-acquired pneumonia in adults across Europe: A literature review. <i>Respiratory Medicine</i> , 2018 , 137, 6-13	4.6	47
334	Meropenem population pharmacokinetics in critically ill patients with septic shock and continuous renal replacement therapy: influence of residual diuresis on dose requirements. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 5520-8	5.9	46
333	Epidemiology, antibiotic therapy and clinical outcomes of healthcare-associated pneumonia in critically ill patients: a Spanish cohort study. <i>Intensive Care Medicine</i> , 2014 , 40, 572-81	14.5	46
332	Impact of neuraminidase inhibitors on influenza A(H1N1)pdm09-related pneumonia: an individual participant data meta-analysis. <i>Influenza and Other Respiratory Viruses</i> , 2016 , 10, 192-204	5.6	46
331	Mechanisms of abnormal gas exchange in patients with pneumonia. <i>Anesthesiology</i> , 1991 , 75, 782-9	4.3	45
330	Multidrug Resistant Gram-Negative Bacteria in Community-Acquired Pneumonia. <i>Critical Care</i> , 2019 , 23, 79	10.8	44
329	Predictors of Severe Sepsis among Patients Hospitalized for Community-Acquired Pneumonia. <i>PLoS ONE</i> , 2016 , 11, e0145929	3.7	44
328	Lymphopenic Community Acquired Pneumonia (L-CAP), an Immunological Phenotype Associated with Higher Risk of Mortality. <i>EBioMedicine</i> , 2017 , 24, 231-236	8.8	43
327	Systemic Biomarkers of Collagen and Elastin Turnover Are Associated With Clinically Relevant Outcomes in COPD. <i>Chest</i> , 2017 , 151, 47-59	5.3	43
326	New guidelines for hospital-acquired pneumonia/ventilator-associated pneumonia: USA vs. Europe. <i>Current Opinion in Critical Care</i> , 2018 , 24, 347-352	3.5	43
325	Community-acquired lung respiratory infections in HIV-infected patients: microbial aetiology and outcome. <i>European Respiratory Journal</i> , 2014 , 43, 1698-708	13.6	42
324	Validation of predictors of adverse outcomes in hospital-acquired pneumonia in the ICU. <i>Critical Care Medicine</i> , 2013 , 41, 2151-61	1.4	42
323	Systemic inflammatory pattern of patients with community-acquired pneumonia with and without COPD. <i>Chest</i> , 2013 , 143, 1009-1017	5.3	42
322	Ventilator-associated pneumonia. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2014 , 35, 469-81	3.9	41
321	Severe community-acquired pneumonia: Characteristics and prognostic factors in ventilated and non-ventilated patients. <i>PLoS ONE</i> , 2018 , 13, e0191721	3.7	41
320	Influence of previous use of inhaled corticoids on the development of pleural effusion in community-acquired pneumonia. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013 , 187, 1241-8	10.2	40

319	A worldwide perspective of nursing home-acquired pneumonia compared with community-acquired pneumonia. <i>Respiratory Care</i> , 2014 , 59, 1078-85	2.1	36
318	Developing definitions for invasive fungal diseases in critically ill adult patients in intensive care units. Protocol of the FUNgal infections Definitions in ICU patients (FUNDICU) project. <i>Mycoses</i> , 2019 , 62, 310-319	5.2	36
317	Importance of <i>Aspergillus</i> spp. isolation in Acute exacerbations of severe COPD: prevalence, factors and follow-up: the FUNGI-COPD study. <i>Respiratory Research</i> , 2014 , 15, 17	7.3	35
316	Sensitivity, Specificity, and Positivity Predictors of the Pneumococcal Urinary Antigen Test in Community-Acquired Pneumonia. <i>Annals of the American Thoracic Society</i> , 2015 , 12, 1482-9	4.7	33
315	Bacteraemia and antibiotic-resistant pathogens in community acquired pneumonia: risk and prognosis. <i>European Respiratory Journal</i> , 2015 , 45, 1353-63	13.6	33
314	Management of severe acute exacerbations of COPD: an updated narrative review. <i>Multidisciplinary Respiratory Medicine</i> , 2018 , 13, 36	3	33
313	Epidemiology of ICU-acquired pneumonia. <i>Current Opinion in Critical Care</i> , 2018 , 24, 325-331	3.5	33
312	Thrombocytosis is a marker of poor outcome in community-acquired pneumonia. <i>Chest</i> , 2013 , 143, 767-775		32
311	Pneumonia. <i>Nature Reviews Disease Primers</i> , 2021 , 7, 25	51.1	31
310	Endothelial adhesion molecules and multiple organ failure in patients with severe sepsis. <i>Cytokine</i> , 2016 , 88, 267-273	4	31
309	A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Iclaprim Vs Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed to be Due to Gram-Positive Pathogens: REVIVE-1. <i>Clinical Infectious Diseases</i> , 2018 , 66, 1222-1229	11.6	30
308	Polymicrobial intensive care unit-acquired pneumonia: prevalence, microbiology and outcome. <i>Critical Care</i> , 2015 , 19, 450	10.8	30
307	Phenotyping community-acquired pneumonia according to the presence of acute respiratory failure and severe sepsis. <i>Respiratory Research</i> , 2014 , 15, 27	7.3	30
306	Effects of bronchoalveolar lavage volume on arterial oxygenation in mechanically ventilated patients with pneumonia. <i>Intensive Care Medicine</i> , 2001 , 27, 384-93	14.5	30
305	Seasonality of pathogens causing community-acquired pneumonia. <i>Respirology</i> , 2017 , 22, 778-785	3.6	29
304	<i>Pseudomonas aeruginosa</i> nosocomial pneumonia: impact of pneumonia classification. <i>Infection Control and Hospital Epidemiology</i> , 2015 , 36, 1190-7	2	29
303	Association between systemic corticosteroids and outcomes of intensive care unit-acquired pneumonia. <i>Critical Care Medicine</i> , 2012 , 40, 2552-61	1.4	29
302	Immunogenicity and crossreactivity of antibodies to the nucleocapsid protein of SARS-CoV-2: utility and limitations in seroprevalence and immunity studies. <i>Translational Research</i> , 2021 , 232, 60-74	11	29

301	What is the clinical relevance of drug-resistant pneumococcus?. <i>Current Opinion in Pulmonary Medicine</i> , 2016 , 22, 227-34	3	29
300	Prognostic assessment in COPD without lung function: the B-AE-D indices. <i>European Respiratory Journal</i> , 2016 , 47, 1635-44	13.6	29
299	Circulating microRNA profiles predict the severity of COVID-19 in hospitalized patients. <i>Translational Research</i> , 2021 , 236, 147-159	11	29
298	Lymphopenic community-acquired pneumonia is associated with a dysregulated immune response and increased severity and mortality. <i>Journal of Infection</i> , 2019 , 78, 423-431	18.9	28
297	Concept for a study design in patients with severe community-acquired pneumonia: A randomised controlled trial with a novel IGM-enriched immunoglobulin preparation - The CIGMA study. <i>Respiratory Medicine</i> , 2015 , 109, 758-67	4.6	28
296	Biomarkers and community-acquired pneumonia: tailoring management with biological data. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2012 , 33, 266-71	3.9	28
295	Continuous control of tracheal cuff pressure for VAP prevention: a collaborative meta-analysis of individual participant data. <i>Annals of Intensive Care</i> , 2015 , 5, 43	8.9	27
294	Acute respiratory distress syndrome in mechanically ventilated patients with community-acquired pneumonia. <i>European Respiratory Journal</i> , 2018 , 51,	13.6	26
293	Phenotypic shift in <i>Pseudomonas aeruginosa</i> populations from cystic fibrosis lungs after 2-week antipseudomonal treatment. <i>Journal of Cystic Fibrosis</i> , 2017 , 16, 222-229	4.1	26
292	Evidence-Based Study Design for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia. <i>Journal of Infectious Diseases</i> , 2019 , 219, 1536-1544	7	26
291	Declining Mortality in Patients With Acute Respiratory Distress Syndrome: An Analysis of the Acute Respiratory Distress Syndrome Network Trials. <i>Critical Care Medicine</i> , 2019 , 47, 315-323	1.4	25
290	Detection of pneumonia associated pathogens using a prototype multiplexed pneumonia test in hospitalized patients with severe pneumonia. <i>PLoS ONE</i> , 2014 , 9, e110566	3.7	25
289	The BRICS (Bronchiectasis Radiologically Indexed CT Score): A Multicenter Study Score for Use in Idiopathic and Postinfective Bronchiectasis. <i>Chest</i> , 2018 , 153, 1177-1186	5.3	24
288	Systemic corticosteroids for community-acquired pneumonia: reasons for use and lack of benefit on outcome. <i>Respirology</i> , 2013 , 18, 263-71	3.6	24
287	Comparison of two prognostic scores (BSI and FACED) in a Spanish cohort of adult patients with bronchiectasis and improvement of the FACED predictive capacity for exacerbations. <i>PLoS ONE</i> , 2017 , 12, e0175171	3.7	24
286	Predictive and prognostic factors in patients with blood-culture-positive community-acquired pneumococcal pneumonia. <i>European Respiratory Journal</i> , 2016 , 48, 797-807	13.6	24
285	Initial Inflammatory Profile in Community-acquired Pneumonia Depends on Time since Onset of Symptoms. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018 , 198, 370-378	10.2	23
284	Polymicrobial community-acquired pneumonia: An emerging entity. <i>Respirology</i> , 2016 , 21, 65-75	3.6	23

283	IgM levels in plasma predict outcome in severe pandemic influenza. <i>Journal of Clinical Virology</i> , 2013 , 58, 564-7	14.5	23
282	Summary of the international clinical guidelines for the management of hospital-acquired and ventilator-acquired pneumonia. <i>ERJ Open Research</i> , 2018 , 4,	3.5	23
281	pneumonia in the twenty-first century: HIV-infected versus HIV-uninfected patients. <i>Expert Review of Anti-Infective Therapy</i> , 2019 , 17, 787-801	5.5	22
280	Year in review in Intensive Care Medicine 2013: I. Acute kidney injury, ultrasound, hemodynamics, cardiac arrest, transfusion, neurocritical care, and nutrition. <i>Intensive Care Medicine</i> , 2014 , 40, 147-59	14.5	22
279	Pneumococcal vaccination. <i>Current Opinion in Infectious Diseases</i> , 2016 , 29, 187-96	5.4	22
278	Therapy with proton-pump inhibitors for gastroesophageal reflux disease does not reduce the risk for severe exacerbations in COPD. <i>Respirology</i> , 2016 , 21, 883-90	3.6	22
277	Community-acquired pneumonia as an emergency condition. <i>Current Opinion in Critical Care</i> , 2018 , 24, 531-539	3.5	22
276	Community-Acquired Pneumonia Patients at Risk for Early and Long-term Cardiovascular Events Are Identified by Cardiac Biomarkers. <i>Chest</i> , 2019 , 156, 1080-1091	5.3	21
275	The clinical positioning of telavancin in Europe. <i>International Journal of Antimicrobial Agents</i> , 2015 , 45, 213-20	14.3	21
274	Community-acquired pneumonia in critically ill very old patients: a growing problem. <i>European Respiratory Review</i> , 2020 , 29,	9.8	21
273	A Phase 3, Randomized, Double-Blind, Multicenter Study To Evaluate the Safety and Efficacy of Intravenous Iclaprim versus Vancomycin for Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed To Be Due to Gram-Positive Pathogens (REVIVE-2 Study). <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	21
272	Endotracheal tubes for critically ill patients: an in vivo analysis of associated tracheal injury, mucociliary clearance, and sealing efficacy. <i>Chest</i> , 2015 , 147, 1327-1335	5.3	21
271	Update in community-acquired and nosocomial pneumonia 2009. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010 , 181, 782-7	10.2	21
270	Chest physiotherapy: An important adjuvant in critically ill mechanically ventilated patients with COVID-19. <i>Respiratory Physiology and Neurobiology</i> , 2020 , 282, 103529	2.8	21
269	Impact of amoxicillin therapy on resistance selection in patients with community-acquired lower respiratory tract infections: a randomized, placebo-controlled study. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 3258-3267	5.1	21
268	Randomized, multicenter trial of lateral Trendelenburg versus semirecumbent body position for the prevention of ventilator-associated pneumonia. <i>Intensive Care Medicine</i> , 2017 , 43, 1572-1584	14.5	20
267	Randomized Trial of Ceftazidime-Avibactam vs Meropenem for Treatment of Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (REPROVE): Analyses per US FDA-Specified End Points. <i>Open Forum Infectious Diseases</i> , 2019 , 6, ofz149	1	20
266	Outcomes in patients with community-acquired pneumonia admitted to the intensive care unit. <i>Respiratory Medicine</i> , 2015 , 109, 743-50	4.6	20

265	Treatment of Community-Acquired Pneumonia in Immunocompromised Adults: A Consensus Statement Regarding Initial Strategies. <i>Chest</i> , 2020 , 158, 1896-1911	5.3	20
264	Can Artificial Intelligence Improve the Management of Pneumonia. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	20
263	Impact of Hypertonic Saline Solutions on Sputum Expectoration and Their Safety Profile in Patients with Bronchiectasis: A Randomized Crossover Trial. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2018 , 31, 281-289	3.8	20
262	Importance of Legionella pneumophila in the etiology of severe community-acquired pneumonia in Santiago, Chile. <i>Chest</i> , 2014 , 145, 290-296	5.3	20
261	Pneumonia presenting with organ dysfunctions: Causative microorganisms, host factors and outcome. <i>Journal of Infection</i> , 2016 , 73, 419-426	18.9	20
260	Biomarkers kinetics in the assessment of ventilator-associated pneumonia response to antibiotics - results from the BioVAP study. <i>Journal of Critical Care</i> , 2017 , 41, 91-97	4	19
259	Factors associated with hospitalization in bronchiectasis exacerbations: a one-year follow-up study. <i>Respiratory Research</i> , 2017 , 18, 176	7.3	19
258	Pulmonary infections complicating ARDS. <i>Intensive Care Medicine</i> , 2020 , 46, 2168-2183	14.5	19
257	Collagen Degradation and Formation Are Elevated in Exacerbated COPD Compared With Stable Disease. <i>Chest</i> , 2018 , 154, 798-807	5.3	19
256	Clinical variables predicting the risk of a hospital stay for longer than 7 days in patients with severe acute exacerbations of chronic obstructive pulmonary disease: a prospective study. <i>Respiratory Research</i> , 2018 , 19, 261	7.3	19
255	Piperacillin population pharmacokinetics in critically ill patients with multiple organ dysfunction syndrome receiving continuous venovenous haemodiafiltration: effect of type of dialysis membrane on dosing requirements. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 1651-9	5.1	18
254	Twenty-year trend in mortality among hospitalized patients with pneumococcal community-acquired pneumonia. <i>PLoS ONE</i> , 2018 , 13, e0200504	3.7	18
253	Exertional hypoxemia in stable COPD is common and predicted by circulating proadrenomedullin. <i>Chest</i> , 2014 , 146, 328-338	5.3	18
252	Microbiology and outcomes of community acquired pneumonia in non cystic-fibrosis bronchiectasis patients. <i>Journal of Infection</i> , 2015 , 71, 28-36	18.9	18
251	An overview of guidelines for the management of hospital-acquired and ventilator-associated pneumonia caused by multidrug-resistant Gram-negative bacteria. <i>Current Opinion in Infectious Diseases</i> , 2019 , 32, 656-662	5.4	18
250	Effect of Combined β -Lactam/Macrolide Therapy on Mortality According to the Microbial Etiology and Inflammatory Status of Patients With Community-Acquired Pneumonia. <i>Chest</i> , 2019 , 155, 795-804	5.3	18
249	Predicting In-Hospital Treatment Failure (≥ 7 days) in Patients with COPD Exacerbation Using Antibiotics and Systemic Steroids. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2016 , 13, 82-92	2	17
248	Lymphocytopenia as a Predictor of Mortality in Patients with ICU-Acquired Pneumonia. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	17

247	Risk factors for multidrug-resistant pathogens in bronchiectasis exacerbations. <i>BMC Infectious Diseases</i> , 2017 , 17, 659	4	17
246	Impact of chronic liver disease in intensive care unit acquired pneumonia: a prospective study. <i>Intensive Care Medicine</i> , 2013 , 39, 1776-84	14.5	17
245	The burden of PCV13 serotypes in hospitalized pneumococcal pneumonia in Spain using a novel urinary antigen detection test. CAPA study. <i>Vaccine</i> , 2017 , 35, 5264-5270	4.1	17
244	Passive smoking at home is a risk factor for community-acquired pneumonia in older adults: a population-based case-control study. <i>BMJ Open</i> , 2014 , 4, e005133	3	17
243	Predictors of treatment failure and clinical stability in patients with community acquired pneumonia. <i>Annals of Translational Medicine</i> , 2017 , 5, 443	3.2	17
242	A multicentre analysis of Nocardia pneumonia in Spain: 2010-2016. <i>International Journal of Infectious Diseases</i> , 2020 , 90, 161-166	10.5	17
241	Clinical management of community acquired pneumonia in the elderly patient. <i>Expert Review of Respiratory Medicine</i> , 2016 , 10, 1211-1220	3.8	17
240	Serum levels of hyaluronic acid are associated with COPD severity and predict survival. <i>European Respiratory Journal</i> , 2019 , 53,	13.6	16
239	Endotracheal tube biofilm translocation in the lateral Trendelenburg position. <i>Critical Care</i> , 2015 , 19, 59	10.8	16
238	A Phase II Randomized, Double-blind, Multicenter Study to Evaluate Efficacy and Safety of Intravenous Iclaprim Versus Vancomycin for the Treatment of Nosocomial Pneumonia Suspected or Confirmed to be Due to Gram-positive Pathogens. <i>Clinical Therapeutics</i> , 2017 , 39, 1706-1718	3.5	16
237	Predicting treatment failure in patients with community acquired pneumonia: a case-control study. <i>Respiratory Research</i> , 2014 , 15, 75	7.3	16
236	Trends in mortality of hospitalised COVID-19 patients: A single centre observational cohort study from Spain. <i>Lancet Regional Health - Europe, The</i> , 2021 , 3, 100041		16
235	The SAATELLITE and EVADE Clinical Studies Within the COMBACTE Consortium: A Public-Private Collaborative Effort in Designing and Performing Clinical Trials for Novel Antibacterial Drugs to Prevent Nosocomial Pneumonia. <i>Clinical Infectious Diseases</i> , 2016 , 63 Suppl 2, S46-51	11.6	16
234	New aspects in the management of pneumonia. <i>Critical Care</i> , 2016 , 20, 267	10.8	16
233	Nosocomial Infection. <i>Critical Care Medicine</i> , 2021 , 49, 169-187	1.4	16
232	SARS-CoV-2-induced Acute Respiratory Distress Syndrome: Pulmonary Mechanics and Gas-Exchange Abnormalities. <i>Annals of the American Thoracic Society</i> , 2020 , 17, 1164-1168	4.7	15
231	Serum levels of immunoglobulins and severity of community-acquired pneumonia. <i>BMJ Open Respiratory Research</i> , 2016 , 3, e000152	5.6	15
230	Intensive care unit patients with lower respiratory tract nosocomial infections: the ENIRRI project. <i>ERJ Open Research</i> , 2017 , 3,	3.5	15

229	Time to blood culture positivity as a predictor of clinical outcomes and severity in adults with bacteremic pneumococcal pneumonia. <i>PLoS ONE</i> , 2017 , 12, e0182436	3.7	15
228	Severe flu management: a point of view. <i>Intensive Care Medicine</i> , 2020 , 46, 153-162	14.5	15
227	Surveillance of iclaprim activity: In vitro susceptibility of gram-positive pathogens collected from 2012 to 2014 from the United States, Asia Pacific, Latin American and Europe. <i>Diagnostic Microbiology and Infectious Disease</i> , 2018 , 90, 329-334	2.9	14
226	Characteristics and Management of Community-Acquired Pneumonia in the Era of Global Aging. <i>Medical Sciences (Basel, Switzerland)</i> , 2018 , 6,	3.3	14
225	Microorganisms resistant to conventional antimicrobials in acute exacerbations of chronic obstructive pulmonary disease. <i>Respiratory Research</i> , 2018 , 19, 119	7.3	14
224	Risk and Prognostic Factors in Very Old Patients with Sepsis Secondary to Community-Acquired Pneumonia. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	14
223	Community-acquired pneumonia in adults: Highlighting missed opportunities for vaccination. <i>European Journal of Internal Medicine</i> , 2017 , 37, 13-18	3.9	14
222	Immunological profiling to assess disease severity and prognosis in community-acquired pneumonia. <i>Lancet Respiratory Medicine</i> , 2017 , 5, e35-e36	35.1	14
221	Inhaled corticosteroids and systemic inflammatory response in community-acquired pneumonia: a prospective clinical study. <i>Respirology</i> , 2014 , 19, 929-35	3.6	14
220	An international perspective on hospitalized patients with viral community-acquired pneumonia. <i>European Journal of Internal Medicine</i> , 2019 , 60, 54-70	3.9	14
219	Pure Viral Sepsis Secondary to Community-Acquired Pneumonia in Adults: Risk and Prognostic Factors. <i>Journal of Infectious Diseases</i> , 2019 , 220, 1166-1171	7	13
218	Evaluation of the Magicplex Sepsis Real-Time Test for the Rapid Diagnosis of Bloodstream Infections in Adults. <i>Frontiers in Cellular and Infection Microbiology</i> , 2019 , 9, 56	5.9	13
217	Discontinuing noninvasive ventilation in severe chronic obstructive pulmonary disease exacerbations: a randomised controlled trial. <i>European Respiratory Journal</i> , 2017 , 50,	13.6	13
216	Ceftobiprole for the treatment of pneumonia: a European perspective. <i>Drug Design, Development and Therapy</i> , 2015 , 9, 4565-72	4.4	13
215	Invasive and non-invasive diagnostic approaches for microbiological diagnosis of hospital-acquired pneumonia. <i>Critical Care</i> , 2019 , 23, 51	10.8	13
214	Invasive Disease vs Urinary Antigen-Confirmed Pneumococcal Community-Acquired Pneumonia. <i>Chest</i> , 2017 , 151, 1311-1319	5.3	12
213	Community-Acquired Pneumococcal Pneumonia in Virologically Suppressed HIV-Infected Adult Patients: A Matched Case-Control Study. <i>Chest</i> , 2017 , 152, 295-303	5.3	12
212	New antimicrobial approaches to gram positive respiratory infections. <i>Pulmonary Pharmacology and Therapeutics</i> , 2015 , 32, 137-43	3.5	12

211	Assessment of a Loop-Mediated Isothermal Amplification (LAMP) Assay for the Rapid Detection of Pathogenic Bacteria from Respiratory Samples in Patients with Hospital-Acquired Pneumonia. <i>Microorganisms</i> , 2020 , 8,	4.9	12
210	Impact of bronchiectasis on outcomes of hospitalized patients with acute exacerbation of chronic obstructive pulmonary disease: A propensity matched analysis. <i>Scientific Reports</i> , 2018 , 8, 9236	4.9	12
209	Mannose-binding lectin protein and its association to clinical outcomes in COPD: a longitudinal study. <i>Respiratory Research</i> , 2015 , 16, 150	7.3	12
208	Diagnosis of pneumonia and monitoring of infection eradication. <i>Drugs</i> , 2000 , 60, 1289-302	12.1	12
207	Inhaled amikacin for severe Gram-negative pulmonary infections in the intensive care unit: current status and future prospects. <i>Critical Care</i> , 2018 , 22, 343	10.8	12
206	Pooled analysis of the phase 3 REVIVE trials: randomised, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin-structure infections. <i>International Journal of Antimicrobial Agents</i> , 2018 , 52, 233-240	14.3	12
205	PES Pathogens in Severe Community-Acquired Pneumonia. <i>Microorganisms</i> , 2019 , 7,	4.9	11
204	IFN β /4 locus polymorphisms and IFN β circulating levels are associated with COPD severity and outcomes. <i>BMC Pulmonary Medicine</i> , 2018 , 18, 51	3.5	11
203	The association of cardiovascular failure with treatment for ventilator-associated lower respiratory tract infection. <i>Intensive Care Medicine</i> , 2019 , 45, 1753-1762	14.5	11
202	Emerging antibiotics for community-acquired pneumonia. <i>Expert Opinion on Emerging Drugs</i> , 2019 , 24, 221-231	3.7	11
201	Neumonía adquirida en la comunidad. Normativa de la Sociedad Española de Neumología y Cirugía Torácica (SEPAR). Actualización 2020. <i>Archivos De Bronconeumología</i> , 2020 , 56, 1-10	0.7	11
200	Predictors of failure with high-flow nasal oxygen therapy in COVID-19 patients with acute respiratory failure: a multicenter observational study. <i>Journal of Intensive Care</i> , 2021 , 9, 23	7	11
199	Community-acquired pneumonia severity assessment tools in patients hospitalized with COVID-19: a validation and clinical applicability study. <i>Clinical Microbiology and Infection</i> , 2021 , 27, 1037.e1-1037.e8	9.5	11
198	Early Bacterial Identification Among Intubated Patients with COVID-19 or Influenza Pneumonia: A European Multicenter Comparative Cohort Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021 ,	10.2	11
197	Upper respiratory symptoms worsen over time and relate to clinical phenotype in chronic obstructive pulmonary disease. <i>Annals of the American Thoracic Society</i> , 2015 , 12, 997-1004	4.7	10
196	Readmission in COPD patients: should we consider it a marker of quality of care or a marker of a more severe disease with a worse prognosis?. <i>European Respiratory Journal</i> , 2016 , 48, 279-81	13.6	10
195	Pneumonic and non-pneumonic exacerbations in bronchiectasis: Clinical and microbiological differences. <i>Journal of Infection</i> , 2018 , 77, 99-106	18.9	10
194	Neuraminidase Inhibitors and Hospital Length of Stay: A Meta-analysis of Individual Participant Data to Determine Treatment Effectiveness Among Patients Hospitalized With Nonfatal 2009 Pandemic Influenza A(H1N1) Virus Infection. <i>Journal of Infectious Diseases</i> , 2020 , 221, 356-366	7	10

193	Severity and outcomes of community acquired pneumonia in asthmatic patients. <i>Respiratory Medicine</i> , 2014 , 108, 1713-22	4.6	10
192	Gender differences in community-acquired pneumonia. <i>Minerva Medica</i> , 2020 , 111, 153-165	2.2	10
191	Coronavirus Disease-19: An Interim Evidence Synthesis of the World Association for Infectious Diseases and Immunological Disorders (Waidid). <i>Frontiers in Medicine</i> , 2020 , 7, 572485	4.9	10
190	The importance of airway and lung microbiome in the critically ill. <i>Critical Care</i> , 2020 , 24, 537	10.8	10
189	Core Outcome Measures for Trials in People With Coronavirus Disease 2019: Respiratory Failure, Multiorgan Failure, Shortness of Breath, and Recovery. <i>Critical Care Medicine</i> , 2021 , 49, 503-516	1.4	10
188	Corticosteroids for CAP, influenza and COVID-19: when, how and benefits or harm?. <i>European Respiratory Review</i> , 2021 , 30,	9.8	10
187	Elaboration of Consensus Clinical Endpoints to Evaluate Antimicrobial Treatment Efficacy in Future Hospital-acquired/Ventilator-associated Bacterial Pneumonia Clinical Trials. <i>Clinical Infectious Diseases</i> , 2019 , 69, 1912-1918	11.6	9
186	Q Fever (Coxiella Burnetii). <i>Seminars in Respiratory and Critical Care Medicine</i> , 2020 , 41, 509-521	3.9	9
185	Emerging drugs for nosocomial pneumonia. <i>Expert Opinion on Emerging Drugs</i> , 2016 , 21, 331-41	3.7	9
184	Antivirals for influenza-Like Illness? A randomised Controlled trial of Clinical and Cost effectiveness in primary CarE (ALIC E): the ALIC E protocol. <i>BMJ Open</i> , 2018 , 8, e021032	3	9
183	Comparative efficacy of linezolid and vancomycin for endotracheal tube MRSA biofilms from ICU patients. <i>Critical Care</i> , 2019 , 23, 251	10.8	9
182	Noninvasive ventilation in withdrawal from mechanical ventilation. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2014 , 35, 507-18	3.9	9
181	CD4+ cell counts and HIV-RNA levels do not predict outcomes of community-acquired pneumonia in hospitalized HIV-infected patients. <i>International Journal of Infectious Diseases</i> , 2011 , 15, e822-7	10.5	9
180	Treatment with macrolides and glucocorticosteroids in severe community-acquired pneumonia: A post-hoc exploratory analysis of a randomized controlled trial. <i>PLoS ONE</i> , 2017 , 12, e0178022	3.7	9
179	Reconsidering ventilator-associated pneumonia from a new dimension of the lung microbiome. <i>EBioMedicine</i> , 2020 , 60, 102995	8.8	9
178	Bridging animal and clinical research during SARS-CoV-2 pandemic: A new-old challenge. <i>EBioMedicine</i> , 2021 , 66, 103291	8.8	9
177	Antibiotic therapy prior to hospital admission is associated with reduced septic shock and need for mechanical ventilation in patients with community-acquired pneumonia. <i>Journal of Infection</i> , 2017 , 74, 442-449	18.9	8
176	Molecular characterization of methicillin-resistant Staphylococcus aureus clinical strains from the endotracheal tubes of patients with nosocomial pneumonia. <i>Antimicrobial Resistance and Infection Control</i> , 2020 , 9, 43	6.2	8

175	Community-acquired bacterial pneumonia in adult HIV-infected patients. <i>Expert Review of Anti-Infective Therapy</i> , 2018 , 16, 579-588	5.5	8
174	Inhaled corticosteroids do not influence the early inflammatory response and clinical presentation of hospitalized subjects with COPD exacerbation. <i>Respiratory Care</i> , 2014 , 59, 1550-9	2.1	8
173	Impact of COPD in the outcome of ICU-acquired pneumonia with and without previous intubation. <i>Chest</i> , 2015 , 147, 1530-1538	5.3	8
172	Is ventilated hospital-acquired pneumonia a worse entity than ventilator-associated pneumonia?. <i>European Respiratory Review</i> , 2020 , 29,	9.8	8
171	Surveillance of iclaprim activity: in vitro susceptibility of Gram-positive skin infection pathogens collected from 2015 to 2016 from North America and Europe. <i>Diagnostic Microbiology and Infectious Disease</i> , 2019 , 93, 154-158	2.9	8
170	Investigational drugs in phase I and phase II clinical trials for the treatment of community-acquired pneumonia. <i>Expert Opinion on Investigational Drugs</i> , 2017 , 26, 1239-1248	5.9	7
169	Emerging strategies for the noninvasive diagnosis of nosocomial pneumonia. <i>Expert Review of Anti-Infective Therapy</i> , 2019 , 17, 523-533	5.5	7
168	Short-Term Appraisal of the Effects and Safety of Manual Versus Ventilator Hyperinflation in an Animal Model of Severe Pneumonia. <i>Respiratory Care</i> , 2019 , 64, 760-770	2.1	7
167	Clinical Management of Bacterial Pneumonia 2015 ,		7
166	Adjuvant therapies in critical care: steroids in community-acquired pneumonia. <i>Intensive Care Medicine</i> , 2018 , 44, 478-481	14.5	7
165	Impact of microbial ecology on accuracy of surveillance cultures to predict multidrug resistant microorganisms causing ventilator-associated pneumonia. <i>Journal of Infection</i> , 2014 , 69, 333-40	18.9	7
164	Streptococcus pneumoniae-associated pneumonia complicated by purulent pericarditis: case series. <i>Jornal Brasileiro De Pneumologia</i> , 2015 , 41, 389-94	1.1	7
163	The strange case of community-acquired pneumonia in COPD. <i>Chest</i> , 2011 , 139, 483-485	5.3	7
162	International Survey to Establish Prioritized Outcomes for Trials in People With Coronavirus Disease 2019. <i>Critical Care Medicine</i> , 2020 , 48, 1612-1621	1.4	7
161	Multilobar bilateral and unilateral chest radiograph involvement: implications for prognosis in hospitalised community-acquired pneumonia. <i>European Respiratory Journal</i> , 2016 , 48, 257-61	13.6	7
160	Adjunctive Therapies for Community-Acquired Pneumonia. <i>Clinics in Chest Medicine</i> , 2018 , 39, 753-764	5.3	7
159	Drugs that increase the risk of community-acquired pneumonia: a narrative review. <i>Expert Opinion on Drug Safety</i> , 2018 , 17, 991-1003	4.1	7
158	Body Position and Ventilator-Associated Pneumonia Prevention. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2017 , 38, 371-380	3.9	6

157	Year in review in Intensive Care Medicine 2014: II. ARDS, airway management, ventilation, adjuvants in sepsis, hepatic failure, symptoms assessment and management, palliative care and support for families, prognostication, organ donation, outcome, organisation and research methodology. <i>Intensive Care Medicine</i> , 2015 , 41, 389-401	14.5	6
156	A Phase 2 Study of Pimodivir (JNJ-63623872) in Combination with Oseltamivir in Elderly and NonElderly Adults Hospitalized with Influenza A Infection: OPAL study. <i>Journal of Infectious Diseases</i> , 2020 ,	7	6
155	Ceftaroline for severe community-acquired pneumonia: A real-world two-centre experience in Italy and Spain. <i>International Journal of Antimicrobial Agents</i> , 2020 , 55, 105921	14.3	6
154	Advances in molecular diagnostic tests for pneumonia. <i>Current Opinion in Pulmonary Medicine</i> , 2020 , 26, 241-248	3	6
153	Association between physical activity and risk of hospitalisation in bronchiectasis. <i>European Respiratory Journal</i> , 2020 , 55,	13.6	6
152	Community-Acquired Legionella Pneumonia in Human Immunodeficiency Virus-Infected Adult Patients: A Matched Case-Control Study. <i>Clinical Infectious Diseases</i> , 2018 , 67, 958-961	11.6	6
151	Detection of human cytomegalovirus in bronchoalveolar lavage of intensive care unit patients. <i>European Respiratory Journal</i> , 2018 , 51,	13.6	6
150	Bacteraemia in outpatients with community-acquired pneumonia. <i>European Respiratory Journal</i> , 2016 , 47, 654-7	13.6	6
149	Clinical Approach to Community-acquired Pneumonia. <i>Journal of Thoracic Imaging</i> , 2018 , 33, 273-281	5.6	6
148	Macrolide therapy is associated with lower mortality in community-acquired bacteraemic pneumonia. <i>Respiratory Medicine</i> , 2018 , 140, 115-121	4.6	6
147	Ventilator-Associated Pneumonia and PaO ₂ /FO Diagnostic Accuracy: Changing the Paradigm?. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	6
146	Professions and Working Conditions Associated With Community-Acquired Pneumonia. <i>Archivos De Bronconeumologia</i> , 2015 , 51, 627-31	0.7	6
145	Fungal pneumonia, chronic respiratory diseases and glucocorticoids. <i>Medical Mycology</i> , 2006 , 44, S207-S211	3.1	6
144	International Perspective on the New 2019 American Thoracic Society/Infectious Diseases Society of America Community-Acquired Pneumonia Guideline: A Critical Appraisal by a Global Expert Panel. <i>Chest</i> , 2020 , 158, 1912-1918	5.3	6
143	The research agenda in VAP/HAP: next steps. <i>Intensive Care Medicine</i> , 2017 , 43, 1389-1391	14.5	5
142	Research in community-acquired pneumonia: the next steps. <i>Intensive Care Medicine</i> , 2017 , 43, 1395-1397	14.5	5
141	Year in review in Intensive Care Medicine 2014: I. Cardiac dysfunction and cardiac arrest, ultrasound, neurocritical care, ICU-acquired weakness, nutrition, acute kidney injury, and miscellaneous. <i>Intensive Care Medicine</i> , 2015 , 41, 179-191	14.5	5
140	Nosocomial pneumonia in the intensive care unit: how should treatment failure be predicted?. <i>Revista Brasileira De Terapia Intensiva</i> , 2014 , 26, 208-11	1.2	5

139	Early and Late Cardiovascular Events in Patients Hospitalized for Community-Acquired Pneumonia. <i>Archivos De Bronconeumologia</i> , 2020 , 56, 551-558	0.7	5
138	635. Efficacy, Pharmacokinetics (PK), and Safety Profile of MEDI3902, an Anti-Pseudomonas aeruginosa Bispecific Human Monoclonal Antibody in Mechanically Ventilated Intensive Care Unit Patients; Results of the Phase 2 EVADE Study Conducted by the Public-Private COMBACTE-MAGNET Consortium in the Innovative Medicines Initiative (IMI) Program. <i>Open Forum</i>	1	5
137	Nonantibiotic Adjunctive Therapies for Community-Acquired Pneumonia (Corticosteroids and Beyond): Where Are We with Them?. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2016 , 37, 913-922	2.9	5
136	Biomarkers in the ICU: less is more? No. <i>Intensive Care Medicine</i> , 2021 , 47, 97-100	14.5	5
135	Criteria and definitions for the radiological and clinical diagnosis of bronchiectasis in adults for use in clinical trials: international consensus recommendations. <i>Lancet Respiratory Medicine</i> , 2021 ,	35.1	5
134	What's new in severe community-acquired pneumonia? Corticosteroids as adjunctive treatment to antibiotics. <i>Intensive Care Medicine</i> , 2016 , 42, 1276-8	14.5	4
133	Mucoid Pseudomonas aeruginosa alters sputum viscoelasticity in patients with non-cystic fibrosis bronchiectasis. <i>Respiratory Medicine</i> , 2019 , 154, 40-46	4.6	4
132	Promoting the use of social networks in pneumonia. <i>Pneumonia (Nathan Qld)</i> , 2020 , 12, 3	2.8	4
131	The efficacy of inhaled antibiotics in non-cystic fibrosis bronchiectasis. <i>Expert Review of Respiratory Medicine</i> , 2018 , 12, 683-691	3.8	4
130	Should ultrasound be included in the initial assessment of respiratory patients?. <i>Lancet Respiratory Medicine</i> , 2014 , 2, 599-600	35.1	4
129	Tracheostomy Timing and Outcome in Severe COVID-19: The WeanTrach Multicenter Study. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	4
128	Is One Sample Enough? Lactam Target Attainment and Penetration into Epithelial Lining Fluid Based on Multiple Bronchoalveolar Lavage Sampling Time Points in a Swine Pneumonia Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	4
127	Systematic review and meta-analysis of the safety of erythromycin compared to clarithromycin in adults and adolescents with pneumonia. <i>Journal of Chemotherapy</i> , 2020 , 32, 1-6	2.3	4
126	Validation of a Prediction Score for Drug-Resistant Microorganisms in Community-acquired Pneumonia. <i>Annals of the American Thoracic Society</i> , 2021 , 18, 257-265	4.7	4
125	The Value of C-Reactive Protein-to-Lymphocyte Ratio in Predicting the Severity of SARS-CoV-2 Pneumonia. <i>Archivos De Bronconeumologia</i> , 2021 , 57, 79-82	0.7	4
124	Early oseltamivir treatment improves survival in critically ill patients with influenza pneumonia. <i>ERJ Open Research</i> , 2021 , 7,	3.5	4
123	The evolution of the ventilatory ratio is a prognostic factor in mechanically ventilated COVID-19 ARDS patients. <i>Critical Care</i> , 2021 , 25, 331	10.8	4
122	Noninvasive Ventilation with Helium/Oxygen in Chronic Obstructive Pulmonary Disease Exacerbations. When Physiologic Improvement Does Not Translate into Clinical Benefit. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017 , 195, 843-844	10.2	3

121	Effect of Corticosteroids on C-Reactive Protein in Patients with Severe Community-Acquired Pneumonia and High Inflammatory Response: The Effect of Lymphopenia. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	3
120	Influenza management with new therapies. <i>Current Opinion in Pulmonary Medicine</i> , 2020 , 26, 215-221	3	3
119	Defining Community-Acquired Pneumonia as a Public Health Threat: Arguments in Favor from Spanish Investigators. <i>Medical Sciences (Basel, Switzerland)</i> , 2020 , 8,	3.3	3
118	Lung abscess due to <i>Streptococcus pneumoniae</i> : a case series and brief review of the literature. <i>Pneumologia I Alergologia Polska</i> , 2014 , 82, 276-85		3
117	Pneumonic versus Nonpneumonic Exacerbations of Chronic Obstructive Pulmonary Disease. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2020 , 41, 817-829	3.9	3
116	Lateral position during severe mono-lateral pneumonia: an experimental study. <i>Scientific Reports</i> , 2020 , 10, 19372	4.9	3
115	The Evolution and Distribution of Pneumococcal Serotypes in Adults Hospitalized With Community-Acquired Pneumonia in Spain Using a Serotype-Specific Urinary Antigen Detection Test: The CAPA Study, 2011-2018. <i>Clinical Infectious Diseases</i> , 2021 , 73, 1075-1085	11.6	3
114	The effects of direct hemoperfusion using a polymyxin B-immobilized column in a pig model of severe <i>Pseudomonas aeruginosa</i> pneumonia. <i>Annals of Intensive Care</i> , 2016 , 6, 58	8.9	3
113	Appraisal of systemic inflammation and diagnostic markers in a porcine model of VAP: secondary analysis from a study on novel preventive strategies. <i>Intensive Care Medicine Experimental</i> , 2018 , 6, 42	3.7	3
112	COVID-19 in young and middle-aged adults: predictors of poor outcome and clinical differences. <i>Infection</i> , 2021 , 1	5.8	3
111	Aspiration pneumonia: A renewed perspective and practical approach. <i>Respiratory Medicine</i> , 2021 , 185, 106485	4.6	3
110	Difficult to treat microorganisms in patients aged over 80 years with community-acquired pneumonia: the prevalence of PES pathogens. <i>European Respiratory Journal</i> , 2020 , 56,	13.6	2
109	How may we improve clinical outcomes for patients hospitalized with acute exacerbations of chronic obstructive pulmonary disease? A narrative review about possible therapeutic and preventive strategies. <i>Expert Review of Respiratory Medicine</i> , 2020 , 14, 493-500	3.8	2
108	Cost-effectiveness Comparison of Ceftazidime/Avibactam Versus Meropenem in the Empirical Treatment of Hospital-acquired Pneumonia, Including Ventilator-associated Pneumonia, in Italy. <i>Clinical Therapeutics</i> , 2020 , 42, 802-817	3.5	2
107	Pneumonia in 2016: towards better care. <i>Lancet Respiratory Medicine</i> , 2016 , 4, 949-951	35.1	2
106	Looking for Predictors of Early Readmission in Chronic Obstructive Pulmonary Disease: Every Effort Is Required. <i>Annals of the American Thoracic Society</i> , 2018 , 15, 1366	4.7	2
105	Optimal approaches to preventing severe community-acquired pneumonia. <i>Expert Review of Respiratory Medicine</i> , 2019 , 13, 1005-1018	3.8	2
104	Evaluation of severity score-guided approaches to macrolide use in community-acquired pneumonia. <i>European Respiratory Journal</i> , 2017 , 50,	13.6	2

103	Response. <i>Chest</i> , 2013 , 144, 1976	5.3	2
102	Reply to Charles et al.. <i>Clinical Infectious Diseases</i> , 2009 , 48, 1796-1797	11.6	2
101	Invasive Pneumococcal Disease Today. <i>Clinical Pulmonary Medicine</i> , 2012 , 19, 191-198	0.3	2
100	COVID-19 in patients aged 80 years and over during the peaks of the first three pandemic waves at a Spanish tertiary hospital. <i>Pneumon</i> , 2021 , 1-6		2
99	Differences between sexes concerning COVID-19-related pneumonia. <i>Panminerva Medica</i> , 2021 ,	2	2
98	Corticosteroids for severe CAP: the pros. <i>Revista Brasileira De Terapia Intensiva</i> , 2015 , 27, 202-4	1.2	2
97	Non-invasive ventilation in palliative care: a systematic review. <i>Minerva Medica</i> , 2019 , 110, 555-563	2.2	2
96	Diagnostic accuracy of Gram staining when predicting staphylococcal hospital-acquired pneumonia and ventilator-associated pneumonia: a systematic review and meta-analysis. <i>Clinical Microbiology and Infection</i> , 2020 , 26, 1456-1463	9.5	2
95	Systemic Inflammatory Response and Outcomes in Community-Acquired Pneumonia Patients Categorized According to the Smoking Habit or Presence of Chronic Obstructive Pulmonary Disease. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	2
94	Lymphopenia Is Associated With Poor Outcomes of Patients With Community-Acquired Pneumonia and Sepsis. <i>Open Forum Infectious Diseases</i> , 2021 , 8, ofab169	1	2
93	Prone position and VAP incidence in the PROSEVA trial: attention to the causal question when interpreting competing risk analysis. <i>Intensive Care Medicine</i> , 2016 , 42, 2119-2120	14.5	2
92	Feasibility of computerized adventitious respiratory sounds to assess the effects of airway clearance techniques in patients with bronchiectasis. <i>Physiotherapy Theory and Practice</i> , 2020 , 36, 1245-1255	1.5	2
91	Pulmonary Angiopathy in Severe COVID-19: Physiological Conclusions Derived from Ventilatory Ratio?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021 , 203, 258-259	10.2	2
90	Methicillin-susceptible staphylococcus aureus in community-acquired pneumonia: Risk factors and outcomes. <i>Journal of Infection</i> , 2021 , 82, 76-83	18.9	2
89	Nebulized antibiotics for ventilator-associated pneumonia: methodological framework for future multicenter randomized controlled trials. <i>Current Opinion in Infectious Diseases</i> , 2021 , 34, 156-168	5.4	2
88	Thrombocytosis during Stable State Predicts Mortality in Bronchiectasis. <i>Annals of the American Thoracic Society</i> , 2021 , 18, 1316-1325	4.7	2
87	Perspectives on synthetic pharmacotherapy for the treatment of nosocomial pneumonia. <i>Expert Opinion on Pharmacotherapy</i> , 2019 , 20, 1439-1448	4	1
86	24th International Symposium on Infections in the Critically Ill Patient. <i>Medical Sciences (Basel, Switzerland)</i> , 2019 , 7,	3.3	1

85	Respiratory infections management: Still a challenge. <i>Pulmonary Pharmacology and Therapeutics</i> , 2015 , 32, 117-8	3.5	1
84	Characteristics and Outcomes in Patients with Ventilator-Associated Pneumonia Who Do or Do Not Develop Acute Respiratory Distress Syndrome. An Observational Study. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	1
83	Ventilator-associated pneumonia: new principles guiding empiric antibiotic therapy. <i>Current Opinion in Infectious Diseases</i> , 2020 , 33, 182-188	5.4	1
82	Association between sepsis at ICU admission and mortality in patients with ICU-acquired pneumonia: An infectious second-hit model. <i>Journal of Critical Care</i> , 2020 , 59, 207-214	4	1
81	Treatment with long acting muscarinic antagonists stimulates serum levels of irisin in patients with COPD. <i>Pulmonary Pharmacology and Therapeutics</i> , 2018 , 48, 111-116	3.5	1
80	The effect of pulmonary surfactant on the in vitro activity of Iclaprim against common respiratory bacterial pathogens. <i>Diagnostic Microbiology and Infectious Disease</i> , 2018 , 90, 64-66	2.9	1
79	The clinical management of lower respiratory tract infections. <i>Expert Review of Respiratory Medicine</i> , 2016 , 10, 441-452	3.8	1
78	Community-acquired Pneumonia and Acute Respiratory Distress Syndrome: Prevalence, Risk, and Prognosis. <i>Clinical Pulmonary Medicine</i> , 2018 , 25, 100-106	0.3	1
77	Addendum: CillBiz, C.; Domined[O]; Nicolini, A.; Torres, A. PES Pathogens in Severe Community-Acquired Pneumonia. <i>Microorganisms</i> 2019 , 7, 168	4.9	1
76	IgA level in plasma as a differential factor for influenza infection in severe viral pneumonia. <i>Journal of Clinical Virology</i> , 2014 , 59, 135-6	14.5	1
75	Has Mortality of Community-Acquired Pneumonia Really Reduced?. <i>Clinical Pulmonary Medicine</i> , 2017 , 24, 258-262	0.3	1
74	Importance of a registered and structured protocol when conducting systematic reviews: comments about nebulized antibiotics for ventilator-associated pneumonia. <i>Critical Care</i> , 2015 , 19, 298	10.8	1
73	DEVELOPMENT AND VALIDATION OF A HIGH PERFORMANCE LIQUID CHROMATOGRAPHY METHOD TO DETERMINE VANCOMYCIN CONCENTRATIONS IN PLASMA AND PIG PULMONARY TISSUE. <i>Journal of Liquid Chromatography and Related Technologies</i> , 2012 , 35, 240-257	1.3	1
72	Reply to van Saene et al.. <i>Intensive Care Medicine</i> , 2009 , 35, 1817-1817	14.5	1
71	Influenza A (H1N1) Pneumonia. <i>Clinical Pulmonary Medicine</i> , 2012 , 19, 246-253	0.3	1
70	Pathophysiology of Pneumonia		1
69	Impact of exposure time in awake prone positioning on clinical outcomes of patients with COVID-19-related acute respiratory failure treated with high-flow nasal oxygen: a multicenter cohort study.. <i>Critical Care</i> , 2022 , 26, 16	10.8	1
68	Early noninvasive ventilation treatment for respiratory failure due to severe community-acquired pneumonia. <i>Minerva Pneumologica</i> , 2019 , 58,	0.8	1

67	A pooled analysis of patients with wound infections in the Phase 3 REVIVE trials: randomized, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin structure infections. <i>Journal of Medical Microbiology</i> , 2020 , 69, 625-630	3.2	1
66	Magicplex™ Sepsis real-time test for the rapid diagnosis of bloodstream infections in adults		1
65	Reply to Musher. <i>Journal of Infectious Diseases</i> , 2020 , 222, 334-335	7	1
64	Aetiological diagnosis in new adult outpatients with bronchiectasis: role of predictors derived from real life experience. <i>Respiratory Medicine</i> , 2020 , 172, 106090	4.6	1
63	Effects of Mechanical Insufflation-Exsufflation on Sputum Volume in Mechanically Ventilated Critically Ill Subjects. <i>Respiratory Care</i> , 2021 , 66, 1371-1379	2.1	1
62	Impact of Cardiovascular Failure in Intensive Care Unit-Acquired Pneumonia: A Single-Center, Prospective Study. <i>Antibiotics</i> , 2021 , 10,	4.9	1
61	Clinical Factors Associated with a Shorter or Longer Course of Antibiotic Treatment in Patients with Exacerbations of Bronchiectasis: A Prospective Cohort Study. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	1
60	Age is a determinant of short-term mortality in patients hospitalized for an acute exacerbation of COPD. <i>Internal and Emergency Medicine</i> , 2021 , 16, 401-408	3.7	1
59	Omadacycline vs moxifloxacin in adults with community-acquired bacterial pneumonia. <i>International Journal of Infectious Diseases</i> , 2021 , 104, 501-509	10.5	1
58	Treating HIV-Positive/Non-AIDS Patients for Community-Acquired Pneumonia with ART. <i>Current Infectious Disease Reports</i> , 2018 , 20, 46	3.9	1
57	Clinical and Microbiological Outcomes of Ceftazidime-Avibactam Treatment in Adults with Gram-Negative Bacteremia: A Subset Analysis from the Phase 3 Clinical Trial Program. <i>Infectious Diseases and Therapy</i> , 2021 , 10, 2399-2414	6.2	1
56	Design and Rationale of a Prospective International Follow-Up Study on Intensive Care Survivors of COVID-19: The Long-Term Impact in Intensive Care Survivors of Coronavirus Disease-19-AFTERCOR. <i>Frontiers in Medicine</i> , 2021 , 8, 738086	4.9	1
55	New guidelines for severe community-acquired pneumonia. <i>Current Opinion in Pulmonary Medicine</i> , 2021 , 27, 210-215	3	1
54	Microbiological Diagnosis of Respiratory Infections in the Immunocompromised		1
53	Diagnosis of Pneumonia in Immunocompromised Patient		1
52	Chronic Non-Infectious Pulmonary Complications in Haematopoietic Stem Cell Transplantation		1
51	Reliability and Minimum Important Difference of Sputum Weight in Bronchiectasis. <i>Respiratory Care</i> , 2020 , 65, 1478-1487	2.1	0
50	Respiratory research networks in Europe and beyond: aims, achievements and aspirations for the 21st century. <i>Breathe</i> , 2017 , 13, 209-215	1.8	0

49	Noninvasive Ventilation and High-Flow Nasal Therapy Administration in Chronic Obstructive Pulmonary Disease Exacerbations. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2020 , 41, 786-797	3.9	○
48	Empiric antibiotics for community-acquired pneumonia in adult patients: a systematic review and a network meta-analysis. <i>Thorax</i> , 2021 , 76, 1020-1031	7.3	○
47	Predictive Performance of Risk Factors for Multidrug-Resistant Pathogens in Nosocomial Pneumonia. <i>Annals of the American Thoracic Society</i> , 2021 , 18, 807-814	4.7	○
46	Strategies for implementation of a multidisciplinary approach to the treatment of nosocomial infections in critically ill patients. <i>Expert Review of Anti-Infective Therapy</i> , 2021 , 19, 759-767	5.5	○
45	Severe Infections Due to Respiratory Viruses.. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2022 , 43, 60-74	3.9	○
44	Ceftaroline Fosamil for the Empiric Treatment of Hospitalized Adults with cSSTI: An Economic Analysis from the Perspective of the Spanish National Health System.. <i>ClinicoEconomics and Outcomes Research</i> , 2022 , 14, 149-161	1.7	○
43	Diagnostic concordance between BioFire [®] FilmArray [®] Pneumonia Panel and culture in patients with COVID-19 pneumonia admitted to intensive care units: the experience of the third wave in eight hospitals in Colombia.. <i>Critical Care</i> , 2022 , 26, 130	10.8	○
42	Identification of circulating microRNA profiles associated with pulmonary function and radiologic features in survivors of SARS-CoV-2-induced ARDS. <i>Emerging Microbes and Infections</i> , 1-67	18.9	○
41	Letter from Spain. <i>Respirology</i> , 2019 , 24, 817-818	3.6	
40	Reply to "Dual Antibiotic Therapy for Outpatient Management of Community-Acquired Pneumonia?". <i>Archivos De Bronconeumologia</i> , 2020 , 56, 766-767	0.7	
39	The safety of antimicrobials for the treatment of community-acquired pneumonia. <i>Expert Opinion on Drug Safety</i> , 2020 , 19, 577-587	4.1	
38	COPD 2017: A Year in Review. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2018 , 15, 118-122		
37	Community acquired pneumonia in asthma: Not a threatening combination. <i>Respiratory Medicine</i> , 2016 , 112, 136	4.6	
36	Response. <i>Chest</i> , 2019 , 156, 415	5.3	
35	Treatment for hospitalized patients with severe community-acquired pneumonia--reply. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 313, 2184-5	27.4	
34	Author's response to CAP and HCAP are different? An unresolved question <i>Thorax</i> , 2014 , 69, 677-8	7.3	
33	Epidemiology of Community-Acquired Pneumonia Outside Hospital	1-4	
32	Empirical Treatment of Community-Acquired Pneumonia: Current Guidelines	63-100	

31	General Pharmacological Considerations in Antibiotic Treatment of Community-Acquired Pneumonia	127-152
30	β-Lactams in the Therapy of Community-Acquired Pneumonia	153-169
29	Macrolides and Ketolides	171-191
28	Non-Responding Pneumonia	213-227
27	Role of Fluoroquinolones in the Treatment of Community-Acquired Pneumonia	193-212
26	Epidemiology of Adult Hospitalized Community-Acquired Pneumonia	5-19
25	Pathogen Directed Antimicrobial Treatment of Pneumonia	101-126
24	Adjunctive Therapy in Community-Acquired Pneumonia	245-262
23	Microbiological Diagnosis of Community-Acquired Pneumonia	43-61
22	Microbial Aetiology and Antibiotic Resistances in Community-Acquired Pneumonia	21-41
21	Influenza and Pneumococcal Vaccination for Prevention of Community-Acquired Pneumonia in Immunocompetent Adults	229-244
20	Influencia de las resistencias bacterianas sobre la eficiencia del tratamiento antibiótico de las agudizaciones de la bronquitis crónica en España. <i>Pharmacoeconomics - Spanish Research Articles</i> , 2006 , 3, 109-122	
19	Perspectives of patients, family members, health professionals and the public on the impact of COVID-19 on mental health.. <i>Journal of Mental Health</i> , 2022 , 1-10	2.7
18	Impact on in-hospital mortality of ceftaroline versus standard of care in community-acquired pneumonia: a propensity-matched analysis. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021 , 41, 271	5.3
17	Development and characterization of a new swine model of invasive pneumococcal pneumonia. <i>Lab Animal</i> , 2021 , 50, 327-335	0.4
16	Personalizing pneumococcal vaccination recommendations: The Saudi Thoracic Society guidelines. <i>Annals of Thoracic Medicine</i> , 2016 , 11, 89-90	2.2
15	A new molecular diagnostic tool for pneumocystis jirovecii-pneumonia (PjP) detection: Results from European multicenter clinical study CS-2011.. <i>Journal of Clinical Oncology</i> , 2013 , 31, e20652-e20652	2.2
14	Economic analysis of ceftaroline fosamil for treating community-acquired pneumonia in Spain. <i>Journal of Medical Economics</i> , 2020 , 23, 148-155	2.4

13	COPD in the Intensive Care Unit. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2020 , 41, 785	3.9
12	Outcomes of Critically Ill Very Old Patients With Community-Acquired Pneumonia and Acute Respiratory Distress Syndrome. <i>Archivos De Bronconeumologia</i> , 2021 ,	0.7
11	Pulse oximetry is an essential tool that saves lives: a call for standardisation. <i>European Respiratory Journal</i> , 2021 , 57,	13.6
10	Response. <i>Chest</i> , 2016 , 150, 757	5.3
9	Reply to Head and Keynan. <i>Clinical Infectious Diseases</i> , 2019 , 68, 1433-1434	11.6
8	Diagnóstico de la neumonía: una necesidad compartida. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2022 ,	0.9
7	Pulmonary Infections in Patients on Chronic Glucocorticoid Treatment283-304	
6	Intensive Care Management in the Immunocompromised Patient with Pulmonary Infiltrates305-323	
5	Current Strategies in the Treatment of Fungal Infections in the Intensive Care Unit Setting349-381	
4	Current Strategies and Future Directions in Cytomegalovirus (CMV) Pneumonitis383-400	
3	Pulmonary Infections in HIV Patients in the Highly Active Antiretroviral Therapy Era117-141	
2	Neutropenia143-196	
1	Ceftaroline in severe community-acquired pneumonia.. <i>Revista Espanola De Quimioterapia</i> , 2022 , 35 Suppl 1, 28-30	1.6